US2022071951A1PendingUtilityA1

Therapeutic agent for inherited bradyarrhythmia

64
Assignee: UNIV OSAKAPriority: Dec 28, 2018Filed: Dec 27, 2019Published: Mar 10, 2022
Est. expiryDec 28, 2038(~12.4 yrs left)· nominal 20-yr term from priority
Inventors:Yoshihiro AsanoSeiji TakashimaNoriaki YamadaToru Yamashita
A61K 31/4741A61P 9/06A61K 31/353
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A therapeutic agent for bradyarrythmia contains the following compound (I) or compound (II) or a pharmacologically acceptable salt thereof as an active component:(wherein, Ph is a phenyl group).

Claims

exact text as granted — not AI-modified
1 . A therapeutic agent for bradyarrythmia containing the following compound (I) or compound (II) or a pharmacologically acceptable salt thereof as an active component: 
       
         
           
           
               
               
           
         
       
       (wherein, Ph is a phenyl group). 
     
     
         2 . The therapeutic agent according to  claim 1 , wherein
 the bradyarrythmia is inherited bradyarrythmia.   
     
     
         3 . The therapeutic agent according to  claim 1 , wherein
 the bradyarrythmia is any of sinus bradycardia, sinus arrest, sinoatrial block and atrioventricular block.   
     
     
         4 . The therapeutic agent according to  claim 1 , wherein
 the bradyarrythmia is any of sinus bradycardia, sinus arrest, sinoatrial block and atrioventricular block and is inherited bradyarrythmia.   
     
     
         5 . The therapeutic agent according to  claim 1 , containing the following compound (I) or a pharmacologically acceptable salt thereof as an active component: 
       
         
           
           
               
               
           
         
       
       (wherein, Ph is a phenyl group). 
     
     
         6 . The therapeutic agent according to  claim 1 , containing the following compound (II) or a pharmacologically acceptable salt thereof as an active component: 
       
         
           
           
               
               
           
         
       
       (wherein, Ph is a phenyl group). 
     
     
         7 . The therapeutic agent according to  claim 1 , wherein
 the bradyarrythmia is an arrhythmia caused by a mutation in the 83rd amino acid from the N-terminus of a KCNJ3 protein from asparagine (N) to histidine (H).   
     
     
         8 . The therapeutic agent according to  claim 1 , wherein
 the bradyarrythmia is an arrhythmia caused by a mutation in the 101st amino acid from the N-terminus of a KCNJ5 protein from tryptophan (W) to cysteine (C).

Join the waitlist — get patent alerts

Track US2022071951A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.